Chemoimmunotherapy

Reengineering tumor immunity

Gang Chen, Leisha A. Emens

Research output: Contribution to journalArticle

Abstract

Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.

Original languageEnglish (US)
Pages (from-to)203-216
Number of pages14
JournalCancer Immunology Immunotherapy
Volume62
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Immunity
Neoplasms
Pharmaceutical Preparations
Antineoplastic Agents
Appointments and Schedules
Tumor Microenvironment
Adaptive Immunity
Therapeutics
Standard of Care
Immunotherapy
Immune System
Melanoma
Prostatic Neoplasms
Cell Death
Drug Therapy

Keywords

  • Chemoimmunotherapy
  • Chemotherapy
  • Clinical trials
  • Cyclophosphamide
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Chemoimmunotherapy : Reengineering tumor immunity. / Chen, Gang; Emens, Leisha A.

In: Cancer Immunology Immunotherapy, Vol. 62, No. 2, 02.2013, p. 203-216.

Research output: Contribution to journalArticle

Chen, Gang ; Emens, Leisha A. / Chemoimmunotherapy : Reengineering tumor immunity. In: Cancer Immunology Immunotherapy. 2013 ; Vol. 62, No. 2. pp. 203-216.
@article{6c1c5bb035e149b8958c3f682f550269,
title = "Chemoimmunotherapy: Reengineering tumor immunity",
abstract = "Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.",
keywords = "Chemoimmunotherapy, Chemotherapy, Clinical trials, Cyclophosphamide, Immunotherapy, Vaccine",
author = "Gang Chen and Emens, {Leisha A.}",
year = "2013",
month = "2",
doi = "10.1007/s00262-012-1388-0",
language = "English (US)",
volume = "62",
pages = "203--216",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Chemoimmunotherapy

T2 - Reengineering tumor immunity

AU - Chen, Gang

AU - Emens, Leisha A.

PY - 2013/2

Y1 - 2013/2

N2 - Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.

AB - Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.

KW - Chemoimmunotherapy

KW - Chemotherapy

KW - Clinical trials

KW - Cyclophosphamide

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84874108466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874108466&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1388-0

DO - 10.1007/s00262-012-1388-0

M3 - Article

VL - 62

SP - 203

EP - 216

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -